Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Medicine Matters rheumatology

  • Be familiar with the abnormalities of the microbiota in children with juvenile idiopathic arthritis
  • Be familiar with early life events that impact the microbiota as well as the risk for juvenile idiopathic arthritis
  • Be familiar with potential mechanisms by which an altered microbiota may be associated with juvenile idiopathic arthritis.
  • Be familiar with the limited current prospects for therapeutic manipulation of the microbiota in children with juvenile idiopathic arthritis